Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir and Elbasvir in HCV Patients with CKD Pre and Post Kidney Transplant
NCT02902120Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of elbasvir + grazoprevir in hepatitis C (HCV) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Sustained Virologic Response at 12 Weeks Post-Treatment. Started May 2017; status: completed.
02
Drugs
elbasvir + grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02902120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902120.